T cell migration in rheumatoid arthritis

Frontiers in Immunology

Volumn 6, Issue JUL, 2015, Pages

  Mellado, Mario ^a   Martínez Muñoz, Laura ^a   Cascio, Graciela ^a   Lucas, Pilar ^a   Pablos, José L ^b   Rodríguez Frade, José Miguel ^a  

^a CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^b Servicio Madrileño de Salud Red de Investigación en Servicios de Salud en Enfermedades Crónicas   (Spain)

Author keywords

Cell migration; Chemokines; Cytokines; Inflammation; Rheumatoid arthritis

Indexed keywords

AUTOANTIGEN; CD4 ANTIGEN; CHEMOKINE; CHEMOKINE RECEPTOR CCR10; CHEMOKINE RECEPTOR CCR6; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; CYTOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GAMMA INTERFERON; GLYCOSAMINOGLYCAN; INTEGRIN; INTERLEUKIN 1BETA; INTERLEUKIN 21; INTERLEUKIN 23; INTERLEUKIN 6; JANUS KINASE; LEUKOCYTE ANTIGEN; P SELECTIN GLYCOPROTEIN LIGAND 1; SELECTIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1;

ANGIOGENESIS; ANTIGEN RECOGNITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELL INTERACTION; CELL MIGRATION; CELL PROLIFERATION; CYTOKINE PRODUCTION; DISEASE COURSE; ENDOTHELIUM CELL; GENE INTERACTION; HUMAN; IMMUNE RESPONSE; INFLAMMATION; MOLECULAR BIOLOGY; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVITIS; T LYMPHOCYTE; TH1 CELL; TH17 CELL;

EID: 84938516052     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00384     Document Type: Review

References (168)

1. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med (2011) 365:2205-19. doi:10.1056/NEJMra1004965
2. Jutley G, Raza K, Buckley CD. New pathogenic insights into rheumatoid arthritis. Curr Opin Rheumatol (2015) 27:249-55. doi:10.1097/BOR.0000000000000174
3. Mohan VK, Ganesan N, Gopalakrishnan R. Association of susceptible genetic markers and autoantibodies in rheumatoid arthritis. J Genet (2014) 93:597-605. doi:10.1007/s12041-014-0380-1
4. Amos CI, Chen WV, Remmers E, Siminovitch KA, Seldin MF, Criswell LA, et al. Data for genetic analysis workshop (GAW) 15 problem 2, genetic causes of rheumatoid arthritis and associated traits. BMC Proc (2007) 1(Suppl 1):S3. doi:10.1186/1753-6561-1-s1-s3
5. Plenge RM, Cotsapas C, Davies L, Price AL, de Bakker PI, Maller J, et al. Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. Nat Genet (2007) 39:1477-82. doi:10.1038/ng.2007.27
6. Plenge RM, Seielstad M, Padyukov L, Lee AT, Remmers EF, Ding B, et al. TRAF1-C5 as a risk locus for rheumatoid arthritis-a genomewide study. N Engl J Med (2007) 357:1199-209. doi:10.1056/NEJMoa073491
7. Remmers EF, Plenge RM, Lee AT, Graham RR, Hom G, Behrens TW, et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med (2007) 357:977-86. doi:10.1056/NEJMoa073003
8. Hughes LB, Reynolds RJ, Brown EE, Kelley JM, Thomson B, Conn DL, et al. Most common single-nucleotide polymorphisms associated with rheumatoid arthritis in persons of European ancestry confer risk of rheumatoid arthritis in African Americans. Arthritis Rheum (2010) 62:3547-53. doi:10.1002/art.27732
9. Okada Y, Wu D, Trynka G, Raj T, Terao C, Ikari K, et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature (2014) 506:376-81. doi:10.1038/nature12873
10. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol (2007) 7:429-42. doi:10.1038/nri2094
11. Komatsu N, Takayanagi H. Autoimmune arthritis: the interface between the immune system and joints. Adv Immunol (2012) 115:45-71. doi:10.1016/B978-0-12-394299-9.00002-3
12. Iwamoto T, Okamoto H, Toyama Y, Momohara S. Molecular aspects of rheumatoid arthritis: chemokines in the joints of patients. FEBS J (2008) 275:4448-55. doi:10.1111/j.1742-4658.2008.06580.x
13. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol (2007) 7:678-89. doi:10.1038/nri2156
14. Nourshargh S, Alon R. Leukocyte migration into inflamed tissues. Immunity (2014) 41:694-707. doi:10.1016/j.immuni.2014.10.008
15. Kinne RW, Stuhlmuller B, Burmester GR. Cells of the synovium in rheumatoid arthritis. Macrophages. Arthritis Res Ther (2007) 9:224. doi:10.1186/ar2333
16. Lundy SK, Sarkar S, Tesmer LA, Fox DA. Cells of the synovium in rheumatoid arthritis. T lymphocytes. Arthritis Res Ther (2007) 9:202. doi:10.1186/ar2107
17. Mauri C, Ehrenstein MR. Cells of the synovium in rheumatoid arthritis. B cells. Arthritis Res Ther (2007) 9:205. doi:10.1186/ar2125
18. Smeets TJ, Kraan MC, Galjaard S, Youssef PP, Smith MD, Tak PP. Analysis of the cell infiltrate and expression of matrix metalloproteinases and granzyme B in paired synovial biopsy specimens from the cartilage-pannus junction in patients with RA. Ann Rheum Dis (2001) 60:561-5. doi:10.1136/ard.60.6.561
19. Wehrens EJ, Prakken BJ, van Wijk F. T cells out of control-impaired immune regulation in the inflamed joint. Nat Rev Rheumatol (2013) 9:34-42. doi:10.1038/nrrheum.2012.149
20. Lutzky V, Hannawi S, Thomas R. Cells of the synovium in rheumatoid arthritis. Dendritic cells. Arthritis Res Ther (2007) 9:219. doi:10.1186/ar2200
21. Wong PK, Quinn JM, Sims NA, van Nieuwenhuijze A, Campbell IK, Wicks IP. Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis. Arthritis Rheum (2006) 54:158-68. doi:10.1002/art.21537
22. Alzabin S, Williams RO. Effector T cells in rheumatoid arthritis: lessons from animal models. FEBS Lett (2011) 585:3649-59. doi:10.1016/j.febslet.2011.04.034
23. Matmati M, Jacques P, Maelfait J, Verheugen E, Kool M, Sze M, et al. A20 (TNFAIP3) deficiency in myeloid cells triggers erosive polyarthritis resembling rheumatoid arthritis. Nat Genet (2011) 43:908-12. doi:10.1038/ng.874
24. Kollias G, Papadaki P, Apparailly F, Vervoordeldonk MJ, Holmdahl R, Baumans V, et al. Animal models for arthritis: innovative tools for prevention and treatment. Ann Rheum Dis (2011) 70:1357-62. doi:10.1136/ard.2010.148551
25. Kadowaki KM, Matsuno H, Tsuji H, Tunru I. CD4+ T cells from collagen-induced arthritic mice are essential to transfer arthritis into severe combined immunodeficient mice. Clin Exp Immunol (1994) 97:212-8. doi:10.1111/j.1365-2249.1994.tb06070.x
26. Petrow PK, Thoss K, Katenkamp D, Brauer R. Adoptive transfer of susceptibility to antigen-induced arthritis into severe combined immunodeficient (SCID) mice: role of CD4+ and CD8+ T cells. Immunol Invest (1996) 25:341-53. doi:10.3109/08820139609059316
27. Bevaart L, Vervoordeldonk MJ, Tak PP. Evaluation of therapeutic targets in animal models of arthritis: how does it relate to rheumatoid arthritis?. Arthritis Rheum (2010) 62:2192-205. doi:10.1002/art.27503
28. Kagari T, Doi H, Shimozato T. The importance of IL-1 beta and TNF-alpha, and the noninvolvement of IL-6, in the development of monoclonal antibody-induced arthritis. J Immunol (2002) 169:1459-66. doi:10.4049/jimmunol.169.3.1459
29. Isaacs JD. Therapeutic T-cell manipulation in rheumatoid arthritis: past, present and future. Rheumatology (Oxford) (2008) 47:1461-8. doi:10.1093/rheumatology/ken163
30. Kremer JM, Dougados M, Emery P, Durez P, Sibilia J, Shergy W, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum (2005) 52:2263-71. doi:10.1002/art.21201
31. Schiff M. Abatacept treatment for rheumatoid arthritis. Rheumatology (2011) 50:437-49. doi:10.1093/rheumatology/keq287
32. van den Berg WB, Miossec P. IL-17 as a future therapeutic target for rheumatoid arthritis. Nat Rev Rheumatol (2009) 5:549-53. doi:10.1038/nrrheum.2009.179
33. Vermeire K, Heremans H, Vandeputte M, Huang S, Billiau A, Matthys P. Accelerated collagen-induced arthritis in IFN-gamma receptor-deficient mice. J Immunol (1997) 158:5507-13.
34. Matthys P, Vermeire K, Mitera T, Heremans H, Huang S, Billiau A. Anti-IL-12 antibody prevents the development and progression of collagen-induced arthritis in IFN-gamma receptor-deficient mice. Eur J Immunol (1998) 28:2143-51. doi:10.1002/(SICI)1521-4141(199807)28:07<2143::AID-IMMU2143>3.0.CO;2-C
35. Nakae S, Nambu A, Sudo K, Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol (2003) 171:6173-7. doi:10.4049/jimmunol.171.11.6173
36. Zwerina K, Koenders M, Hueber A, Marijnissen RJ, Baum W, Heiland GR, et al. Anti IL-17A therapy inhibits bone loss in TNF-alpha-mediated murine arthritis by modulation of the T-cell balance. Eur J Immunol (2012) 42:413-23. doi:10.1002/eji.201141871
37. Lubberts E, Koenders MI, Oppers-Walgreen B, van den Bersselaar L, Coenen-de Roo CJ, Joosten LA, et al. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum (2004) 50:650-9. doi:10.1002/art.20001
38. Lubberts E, Joosten LA, van de Loo FA, Schwarzenberger P, Kolls J, van den Berg WB. Overexpression of IL-17 in the knee joint of collagen type II immunized mice promotes collagen arthritis and aggravates joint destruction. Inflamm Res (2002) 51:102-4. doi:10.1007/BF02684010
39. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol (2007) 8:942-9. doi:10.1038/ni1496
40. Estrada-Capetillo L, Hernandez-Castro B, Monsivais-Urenda A, Alvarez-Quiroga C, Layseca-Espinosa E, Abud-Mendoza C, et al. Induction of Th17 lymphocytes and Treg cells by monocyte-derived dendritic cells in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Dev Immunol (2013) 2013:584303. doi:10.1155/2013/584303
41. Moret FM, Hack CE, van der Wurff-Jacobs KM, de Jager W, Radstake TR, Lafeber FP, et al. Intra-articular CD1c-expressing myeloid dendritic cells from rheumatoid arthritis patients express a unique set of T cell-attracting chemokines and spontaneously induce Th1, Th17 and Th2 cell activity. Arthritis Res Ther (2013) 15:R155. doi:10.1186/ar4338
42. Segura E, Touzot M, Bohineust A, Cappuccio A, Chiocchia G, Hosmalin A, et al. Human inflammatory dendritic cells induce Th17 cell differentiation. Immunity (2013) 38:336-48. doi:10.1016/j.immuni.2012.10.018
43. Luckey D, Gomez A, Murray J, White B, Taneja V. Bugs & us: the role of the gut in autoimmunity. Indian J Med Res (2013) 138:732-43.
44. Rogier R, Koenders MI, Abdollahi-Roodsaz S. Toll-like receptor mediated modulation of T cell response by commensal intestinal microbiota as a trigger for autoimmune arthritis. J Immunol Res (2015) 2015:527696. doi:10.1155/2015/527696
45. Scher JU, Abramson SB. The microbiome and rheumatoid arthritis. Nat Rev Rheumatol (2011) 7:569-78. doi:10.1038/nrrheum.2011.121
46. Onishi RM, Gaffen SL. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology (2010) 129:311-21. doi:10.1111/j.1365-2567.2009.03240.x
47. Shen F, Ruddy MJ, Plamondon P, Gaffen SL. Cytokines link osteoblasts and inflammation: microarray analysis of interleukin-17-and TNF-alpha-induced genes in bone cells. J Leukoc Biol (2005) 77:388-99. doi:10.1189/jlb.0904490
48. Hsu HC, Yang P, Wang J, Wu Q, Myers R, Chen J, et al. Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat Immunol (2008) 9:166-75. doi:10.1038/ni1552
49. Hsu HC, Zhou T, Kim H, Barnes S, Yang P, Wu Q, et al. Production of a novel class of polyreactive pathogenic autoantibodies in BXD2 mice causes glomerulonephritis and arthritis. Arthritis Rheum (2006) 54:343-55. doi:10.1002/art.21550
50. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest (1999) 103:1345-52. doi:10.1172/JCI5703
51. Kellner H. Targeting interleukin-17 in patients with active rheumatoid arthritis: rationale and clinical potential. Ther Adv Musculoskelet Dis (2013) 5:141-52. doi:10.1177/1759720X13485328
52. Raphael I, Nalawade S, Eagar TN, Forsthuber TG. T cell subsets and their signature cytokines in autoimmune and inflammatory diseases. Cytokine (2015) 74:5-17. doi:10.1016/j.cyto.2014.09.011
53. Zhang L, Li YG, Li YH, Qi L, Liu XG, Yuan CZ, et al. Increased frequencies of Th22 cells as well as Th17 cells in the peripheral blood of patients with ankylosing spondylitis and rheumatoid arthritis. PLoS One (2012) 7:e31000. doi:10.1371/journal.pone.0031000
54. Zhao L, Jiang Z, Jiang Y, Ma N, Zhang Y, Feng L, et al. IL-22+ CD4+ T cells in patients with rheumatoid arthritis. Int J Rheum Dis (2013) 16:518-26. doi:10.1111/1756-185X.12099
55. da Rocha LF Jr, Duarte AL, Dantas AT, Mariz HA, Pitta Ida R, Galdino SL, et al. Increased serum interleukin 22 in patients with rheumatoid arthritis and correlation with disease activity. J Rheumatol (2012) 39:1320-5. doi:10.3899/jrheum.111027
56. Kim KW, Kim HR, Park JY, Park JS, Oh HJ, Woo YJ, et al. Interleukin-22 promotes osteoclastogenesis in rheumatoid arthritis through induction of RANKL in human synovial fibroblasts. Arthritis Rheum (2012) 64:1015-23. doi:10.1002/art.33446
57. Geboes L, Dumoutier L, Kelchtermans H, Schurgers E, Mitera T, Renauld JC, et al. Proinflammatory role of the Th17 cytokine interleukin-22 in collagen-induced arthritis in C57BL/6 mice. Arthritis Rheum (2009) 60:390-5. doi:10.1002/art.24220
58. Sarkar S, Zhou X, Justa S, Bommireddy SR. Interleukin-22 reduces the severity of collagen-induced arthritis in association with increased levels of interleukin-10. Arthritis Rheum (2013) 65:960-71. doi:10.1002/art.37849
59. Justa S, Zhou X, Sarkar S. Endogenous IL-22 plays a dual role in arthritis: regulation of established arthritis via IFN-gamma responses. PLoS One (2014) 9:e93279. doi:10.1371/journal.pone.0093279
60. Chen X, Baumel M, Mannel DN, Howard OM, Oppenheim JJ. Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells. J Immunol (2007) 179:154-61. doi:10.4049/jimmunol.179.1.154
61. Goldstein I, Ben-Horin S, Koltakov A, Chermoshnuk H, Polevoy V, Berkun Y, et al. alpha1beta1 Integrin+ and regulatory Foxp3+ T cells constitute two functionally distinct human CD4+ T cell subsets oppositely modulated by TNFalpha blockade. J Immunol (2007) 178:201-10. doi:10.4049/jimmunol.178.1.201
62. Herrath J, Muller M, Amoudruz P, Janson P, Michaelsson J, Larsson PT, et al. The inflammatory milieu in the rheumatic joint reduces regulatory T-cell function. Eur J Immunol (2011) 41:2279-90. doi:10.1002/eji.201041004
63. Beriou G, Costantino CM, Ashley CW, Yang L, Kuchroo VK, Baecher-Allan C, et al. IL-17-producing human peripheral regulatory T cells retain suppressive function. Blood (2009) 113:4240-9. doi:10.1182/blood-2008-10-183251
64. Koenen HJ, Smeets RL, Vink PM, van Rijssen E, Boots AM, Joosten I. Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood (2008) 112:2340-52. doi:10.1182/blood-2008-01-133967
65. Nie H, Zheng Y, Li R, Guo TB, He D, Fang L, et al. Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF-alpha in rheumatoid arthritis. Nat Med (2013) 19:322-8. doi:10.1038/nm.3085
66. Xu L, Kitani A, Fuss I, Strober W. Cutting edge: regulatory T cells induce CD4+CD25-Foxp3-T cells or are self-induced to become Th17 cells in the absence of exogenous TGF-beta. J Immunol (2007) 178:6725-9. doi:10.4049/jimmunol.178.11.6725
67. Yang XO, Nurieva R, Martinez GJ, Kang HS, Chung Y, Pappu BP, et al. Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity (2008) 29:44-56. doi:10.1016/j.immuni.2008.05.007
68. Cosmi L, Cimaz R, Maggi L, Santarlasci V, Capone M, Borriello F, et al. Evidence of the transient nature of the Th17 phenotype of CD4+CD161+ T cells in the synovial fluid of patients with juvenile idiopathic arthritis. Arthritis Rheum (2011) 63:2504-15. doi:10.1002/art.30332
69. Nistala K, Adams S, Cambrook H, Ursu S, Olivito B, de Jager W, et al. Th17 plasticity in human autoimmune arthritis is driven by the inflammatory environment. Proc Natl Acad Sci U S A (2010) 107:14751-6. doi:10.1073/pnas.1003852107
70. Nistala K, Moncrieffe H, Newton KR, Varsani H, Hunter P, Wedderburn LR. Interleukin-17-producing T cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T cell numbers. Arthritis Rheum (2008) 58:875-87. doi:10.1002/art.23291
71. Snir O, Backlund J, Bostrom J, Andersson I, Kihlberg J, Buckner JH, et al. Multifunctional T cell reactivity with native and glycosylated type II collagen in rheumatoid arthritis. Arthritis Rheum (2012) 64:2482-8. doi:10.1002/art.34459
72. Wilson CB, Rowell E, Sekimata M. Epigenetic control of T-helper-cell differentiation. Nat Rev Immunol (2009) 9:91-105. doi:10.1038/nri2487
73. Chu CQ, Field M, Feldmann M, Maini RN. Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum (1991) 34:1125-32. doi:10.1002/art.1780340908
74. Deleuran BW, Chu CQ, Field M, Brennan FM, Mitchell T, Feldmann M, et al. Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis. Implications for local actions of tumor necrosis factor alpha. Arthritis Rheum (1992) 35:1170-8. doi:10.1002/art.1780351009
75. Dayer JM, Beutler B, Cerami A. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med (1985) 162:2163-8. doi:10.1084/jem.162.6.2163
76. Azuma Y, Kaji K, Katogi R, Takeshita S, Kudo A. Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts. J Biol Chem (2000) 275:4858-64. doi:10.1074/jbc.275.7.4858
77. Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest (2008) 118:3537-45. doi:10.1172/JCI36389
78. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A (1992) 89:9784-8. doi:10.1073/pnas.89.20.9784
79. Malottki K, Barton P, Tsourapas A, Uthman AO, Liu Z, Routh K, et al. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. Health Technol Assess (2011) 15:1-278. doi:10.3310/hta15140
80. Kay J, Calabrese L. The role of interleukin-1 in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) (2004) 43(Suppl 3):iii2-9. doi:10.1093/rheumatology/keh201
81. Nakae S, Saijo S, Horai R, Sudo K, Mori S, Iwakura Y. IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc Natl Acad Sci U S A (2003) 100:5986-90. doi:10.1073/pnas.1035999100
82. McInnes IB, Liew FY, Gracie JA. Interleukin-18: a therapeutic target in rheumatoid arthritis?. Arthritis Res Ther (2005) 7:38-41. doi:10.1186/ar1497
83. Plater-Zyberk C, Joosten LA, Helsen MM, Sattonnet-Roche P, Siegfried C, Alouani S, et al. Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis. J Clin Invest (2001) 108:1825-32. doi:10.1172/JCI200112097
84. Wei XQ, Leung BP, Arthur HM, McInnes IB, Liew FY. Reduced incidence and severity of collagen-induced arthritis in mice lacking IL-18. J Immunol (2001) 166:517-21. doi:10.4049/jimmunol.166.1.517
85. Kishimoto T. Interleukin-6: from basic science to medicine-40 years in immunology. Annu Rev Immunol (2005) 23:1-21. doi:10.1146/annurev.immunol.23.021704.115806
86. Md Yusof MY, Emery P. Targeting interleukin-6 in rheumatoid arthritis. Drugs (2013) 73:341-56. doi:10.1007/s40265-013-0018-2
87. Pope RM, Shahrara S. Possible roles of IL-12-family cytokines in rheumatoid arthritis. Nat Rev Rheumatol (2013) 9:252-6. doi:10.1038/nrrheum.2012.170
88. Joosten LA, Lubberts E, Helsen MM, van den Berg WB. Dual role of IL-12 in early and late stages of murine collagen type II arthritis. J Immunol (1997) 159:4094-102.
89. Pope RM. Apoptosis as a therapeutic tool in rheumatoid arthritis. Nat Rev Immunol (2002) 2:527-35. doi:10.1038/nri846
90. Patel KD, Cuvelier SL, Wiehler S. Selectins: critical mediators of leukocyte recruitment. Semin Immunol (2002) 14:73-81. doi:10.1006/smim.2001.0344
91. Zarbock A, Ley K, McEver RP, Hidalgo A. Leukocyte ligands for endothelial selectins: specialized glycoconjugates that mediate rolling and signaling under flow. Blood (2011) 118:6743-51. doi:10.1182/blood-2011-07-343566
92. Tak PP, Taylor PC, Breedveld FC, Smeets TJ, Daha MR, Kluin PM, et al. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum (1996) 39:1077-81. doi:10.1002/art.1780390702
93. Ates A, Kinikli G, Turgay M, Duman M. Serum-soluble selectin levels in patients with rheumatoid arthritis and systemic sclerosis. Scand J Immunol (2004) 59:315-20. doi:10.1111/j.0300-9475.2004.01389.x
94. Bullard DC, Mobley JM, Justen JM, Sly LM, Chosay JG, Dunn CJ, et al. Acceleration and increased severity of collagen-induced arthritis in P-selectin mutant mice. J Immunol (1999) 163:2844-9.
95. Tarrant TK, Patel DD. Chemokines and leukocyte trafficking in rheumatoid arthritis. Pathophysiology (2006) 13:1-14. doi:10.1016/j.pathophys.2005.11.001
96. Boisvert M, Gendron S, Chetoui N, Aoudjit F. Alpha2 beta1 integrin signaling augments T cell receptor-dependent production of interferon-gamma in human T cells. Mol Immunol (2007) 44:3732-40. doi:10.1016/j.molimm.2007.04.003
97. de Fougerolles AR, Sprague AG, Nickerson-Nutter CL, Chi-Rosso G, Rennert PD, Gardner H, et al. Regulation of inflammation by collagen-binding integrins alpha1beta1 and alpha2beta1 in models of hypersensitivity and arthritis. J Clin Invest (2000) 105:721-9. doi:10.1172/JCI7911
98. Burne MJ, Elghandour A, Haq M, Saba SR, Norman J, Condon T, et al. IL-1 and TNF independent pathways mediate ICAM-1/VCAM-1 up-regulation in ischemia reperfusion injury. J Leukoc Biol (2001) 70:192-8.
99. Lowin T, Straub RH. Integrins and their ligands in rheumatoid arthritis. Arthritis Res Ther (2011) 13:244. doi:10.1186/ar3464
100. Schwartz MA, Assoian RK. Integrins and cell proliferation: regulation of cyclin-dependent kinases via cytoplasmic signaling pathways. J Cell Sci (2001) 114:2553-60.
101. Stupack DG, Cheresh DA. Integrins and angiogenesis. Curr Top Dev Biol (2004) 64:207-38. doi:10.1016/S0070-2153(04)64009-9
102. Yusuf-Makagiansar H, Anderson ME, Yakovleva TV, Murray JS, Siahaan TJ. Inhibition of LFA-1/ICAM-1 and VLA-4/VCAM-1 as a therapeutic approach to inflammation and autoimmune diseases. Med Res Rev (2002) 22:146-67. doi:10.1002/med.10001
103. Klimiuk PA, Sierakowski S, Latosiewicz R, Cylwik JP, Cylwik B, Skowronski J, et al. Soluble adhesion molecules (ICAM-1, VCAM-1, and E-selectin) and vascular endothelial growth factor (VEGF) in patients with distinct variants of rheumatoid synovitis. Ann Rheum Dis (2002) 61:804-9. doi:10.1136/ard.61.9.804
104. Bullard DC, Hurley LA, Lorenzo I, Sly LM, Beaudet AL, Staite ND. Reduced susceptibility to collagen-induced arthritis in mice deficient in intercellular adhesion molecule-1. J Immunol (1996) 157:3153-8.
105. Kavanaugh AF, Davis LS, Jain RI, Nichols LA, Norris SH, Lipsky PE. A phase I/II open label study of the safety and efficacy of an anti-ICAM-1 (intercellular adhesion molecule-1; CD54) monoclonal antibody in early rheumatoid arthritis. J Rheumatol (1996) 23:1338-44.
106. Contento RL, Campello S, Trovato AE, Magrini E, Anselmi F, Viola A. Adhesion shapes T cells for prompt and sustained T-cell receptor signalling. EMBO J (2010) 29:4035-47. doi:10.1038/emboj.2010.258
107. Montresor A, Toffali L, Constantin G, Laudanna C. Chemokines and the signaling modules regulating integrin affinity. Front Immunol (2012) 3:127. doi:10.3389/fimmu.2012.00127
108. Cascio G, Martin-Cofreces NB, Rodriguez-Frade JM, Lopez-Cotarelo P, Criado G, Pablos JL, et al. CXCL12 regulates through JAK1 and JAK2 formation of productive immunological synapses. J Immunol (2015) 194(11):5509-19. doi:10.4049/jimmunol.1402419
109. Garcia-Bernal D, Parmo-Cabanas M, Dios-Esponera A, Samaniego R, Hernán-P de la Ossa D, Teixido J. Chemokine-induced Zap70 kinase-mediated dissociation of the Vav1-talin complex activates alpha4beta1 integrin for T cell adhesion. Immunity (2009) 31:953-64. doi:10.1016/j.immuni.2009.09.021
110. Perez-Rivero G, Cascio G, Soriano SF, Sanz AG, de Guinoa JS, Rodriguez-Frade JM, et al. Janus kinases 1 and 2 regulate chemokine-mediated integrin activation and naive T-cell homing. Eur J Immunol (2013) 43:1745-57. doi:10.1002/eji.201243178
111. O'Connor P. Natalizumab and the role of alpha 4-integrin antagonism in the treatment of multiple sclerosis. Expert Opin Biol Ther (2007) 7:123-36. doi:10.1517/14712598.7.1.123
112. Eksteen B, Adams DH. GSK-1605786, a selective small-molecule antagonist of the CCR9 chemokine receptor for the treatment of Crohn's disease. IDrugs (2010) 13:472-81.
113. Walters MJ, Wang Y, Lai N, Baumgart T, Zhao BN, Dairaghi DJ, et al. Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease. J Pharmacol Exp Ther (2010) 335:61-9. doi:10.1124/jpet.110.169714
114. Ni H, Moe S, Myint KT, Htet A. Oral Janus kinase inhibitor for the treatment of rheumatoid arthritis: tofacitinib. ISRN Rheumatol (2013) 2013:357904. doi:10.1155/2013/357904
115. Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med (2012) 367:495-507. doi:10.1056/NEJMoa1109071
116. Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, Magilavy DB. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med (2010) 363:1303-12. doi:10.1056/NEJMoa1000500
117. Kelly V, Genovese M. Novel small molecule therapeutics in rheumatoid arthritis. Rheumatology (Oxford) (2013) 52:1155-62. doi:10.1093/rheumatology/kes367
118. Whang JA, Chang BY. Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis. Drug Discov Today (2014) 19:1200-4. doi:10.1016/j.drudis.2014.03.028
119. Gerard C, Rollins BJ. Chemokines and disease. Nat Immunol (2001) 2:108-15. doi:10.1038/84209
120. Buckley CD, Amft N, Bradfield PF, Pilling D, Ross E, Arenzana-Seisdedos F, et al. Persistent induction of the chemokine receptor CXCR4 by TGF-beta 1 on synovial T cells contributes to their accumulation within the rheumatoid synovium. J Immunol (2000) 165:3423-9. doi:10.4049/jimmunol.165.6.3423
121. Nanki T, Hayashida K, El-Gabalawy HS, Suson S, Shi K, Girschick HJ, et al. Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4+ T cell accumulation in rheumatoid arthritis synovium. J Immunol (2000) 165:6590-8. doi:10.4049/jimmunol.165.11.6590
122. Alaaeddine N, Olee T, Hashimoto S, Creighton-Achermann L, Lotz M. Production of the chemokine RANTES by articular chondrocytes and role in cartilage degradation. Arthritis Rheum (2001) 44:1633-43. doi:10.1002/1529-0131(200107)44:7<1633::AID-ART286>3.0.CO;2-Z
123. Borzi RM, Mazzetti I, Cattini L, Uguccioni M, Baggiolini M, Facchini A. Human chondrocytes express functional chemokine receptors and release matrix-degrading enzymes in response to C-X-C and C-C chemokines. Arthritis Rheum (2000) 43:1734-41. doi:10.1002/1529-0131(200008)43:8<1734::AID-ANR9>3.0.CO;2-B
124. Wei L, Sun X, Kanbe K, Wang Z, Sun C, Terek R, et al. Chondrocyte death induced by pathological concentration of chemokine stromal cell-derived factor-1. J Rheumatol (2006) 33:1818-26.
125. Garcia-Vicuna R, Gomez-Gaviro MV, Dominguez-Luis MJ, Pec MK, Gonzalez-Alvaro I, Alvaro-Gracia JM, et al. CC and CXC chemokine receptors mediate migration, proliferation, and matrix metalloproteinase production by fibroblast-like synoviocytes from rheumatoid arthritis patients. Arthritis Rheum (2004) 50:3866-77. doi:10.1002/art.20615
126. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol (2009) 27:485-517. doi:10.1146/annurev.immunol.021908.132710
127. Lim HW, Lee J, Hillsamer P, Kim CH. Human Th17 cells share major trafficking receptors with both polarized effector T cells and FOXP3+ regulatory T cells. J Immunol (2008) 180:122-9. doi:10.4049/jimmunol.180.1.122
128. Paulissen SM, van Hamburg JP, Dankers W, Lubberts E. The role and modulation of CCR6+ Th17 cell populations in rheumatoid arthritis. Cytokine (2015) 74(1):43-53. doi:10.1016/j.cyto.2015.02.002
129. Tak PP. Chemokine inhibition in inflammatory arthritis. Best Pract Res Clin Rheumatol (2006) 20:929-39. doi:10.1016/j.berh.2006.06.001
130. De Benedetti F, Pignatti P, Bernasconi S, Gerloni V, Matsushima K, Caporali R, et al. Interleukin 8 and monocyte chemoattractant protein-1 in patients with juvenile rheumatoid arthritis. Relation to onset types, disease activity, and synovial fluid leukocytes. J Rheumatol (1999) 26:425-31.
131. Harada A, Sekido N, Akahoshi T, Wada T, Mukaida N, Matsushima K. Essential involvement of interleukin-8 (IL-8) in acute inflammation. J Leukoc Biol (1994) 56:559-64.
132. Iwamoto T, Okamoto H, Kobayashi S, Ikari K, Toyama Y, Tomatsu T, et al. A role of monocyte chemoattractant protein-4 (MCP-4)/CCL13 from chondrocytes in rheumatoid arthritis. FEBS J (2007) 274:4904-12. doi:10.1111/j.1742-4658.2007.06013.x
133. Koch AE, Kunkel SL, Harlow LA, Johnson B, Evanoff HL, Haines GK, et al. Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. J Clin Invest (1992) 90:772-9. doi:10.1172/JCI115950
134. Luster AD. Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med (1998) 338:436-45. doi:10.1056/NEJM199802123380706
135. Ogata H, Takeya M, Yoshimura T, Takagi K, Takahashi K. The role of monocyte chemoattractant protein-1 (MCP-1) in the pathogenesis of collagen-induced arthritis in rats. J Pathol (1997) 182:106-14. doi:10.1002/(SICI)1096-9896(199705)182:1<106::AID-PATH816>3.0.CO;2-A
136. Gong JH, Ratkay LG, Waterfield JD, Clark-Lewis I. An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-lpr mouse model. J Exp Med (1997) 186:131-7. doi:10.1084/jem.186.1.131
137. Bruhl H, Cihak J, Schneider MA, Plachy J, Rupp T, Wenzel I, et al. Dual role of CCR2 during initiation and progression of collagen-induced arthritis: evidence for regulatory activity of CCR2+ T cells. J Immunol (2004) 172:890-8. doi:10.4049/jimmunol.172.2.890
138. Quinones MP, Estrada CA, Kalkonde Y, Ahuja SK, Kuziel WA, Mack M, et al. The complex role of the chemokine receptor CCR2 in collagen-induced arthritis: implications for therapeutic targeting of CCR2 in rheumatoid arthritis. J Mol Med (Berl) (2005) 83:672-81. doi:10.1007/s00109-005-0637-5
139. Zhao Q. Dual targeting of CCR2 and CCR5: therapeutic potential for immunologic and cardiovascular diseases. J Leukoc Biol (2010) 88:41-55. doi:10.1189/jlb.1009671
140. Rathanaswami P, Hachicha M, Sadick M, Schall TJ, McColl SR. Expression of the cytokine RANTES in human rheumatoid synovial fibroblasts. Differential regulation of RANTES and interleukin-8 genes by inflammatory cytokines. J Biol Chem (1993) 268:5834-9.
141. Volin MV, Shah MR, Tokuhira M, Haines GK, Woods JM, Koch AE. RANTES expression and contribution to monocyte chemotaxis in arthritis. Clin Immunol Immunopathol (1998) 89:44-53. doi:10.1006/clin.1998.4590
142. Koch AE, Kunkel SL, Harlow LA, Mazarakis DD, Haines GK, Burdick MD, et al. Macrophage inflammatory protein-1 alpha. A novel chemotactic cytokine for macrophages in rheumatoid arthritis. J Clin Invest (1994) 93:921-8. doi:10.1172/JCI117097
143. Patel DD, Zachariah JP, Whichard LP. CXCR3 and CCR5 ligands in rheumatoid arthritis synovium. Clin Immunol (2001) 98:39-45. doi:10.1006/clim.2000.4957
144. Haringman JJ, Smeets TJ, Reinders-Blankert P, Tak PP. Chemokine and chemokine receptor expression in paired peripheral blood mononuclear cells and synovial tissue of patients with rheumatoid arthritis, osteoarthritis, and reactive arthritis. Ann Rheum Dis (2006) 65:294-300. doi:10.1136/ard.2005.037176
145. Weber C, Weber KS, Klier C, Gu S, Wank R, Horuk R, et al. Specialized roles of the chemokine receptors CCR1 and CCR5 in the recruitment of monocytes and T(H)1-like/CD45RO(+) T cells. Blood (2001) 97:1144-6. doi:10.1182/blood.V97.4.1144
146. Yang YF, Mukai T, Gao P, Yamaguchi N, Ono S, Iwaki H, et al. A non-peptide CCR5 antagonist inhibits collagen-induced arthritis by modulating T cell migration without affecting anti-collagen T cell responses. Eur J Immunol (2002) 32:2124-32. doi:10.1002/1521-4141(200208)32:8<2124::AID-IMMU2124>3.0.CO;2-S
147. Vierboom MP, Zavodny PJ, Chou CC, Tagat JR, Pugliese-Sivo C, Strizki J, et al. Inhibition of the development of collagen-induced arthritis in rhesus monkeys by a small molecular weight antagonist of CCR5. Arthritis Rheum (2005) 52:627-36. doi:10.1002/art.20850
148. Zapico I, Coto E, Rodriguez A, Alvarez C, Torre JC, Alvarez V. CCR5 (chemokine receptor-5) DNA-polymorphism influences the severity of rheumatoid arthritis. Genes Immun (2000) 1:288-9. doi:10.1038/sj.gene.6363673
149. Desmetz C, Lin YL, Mettling C, Portales P, Noel D, Clot J, et al. Cell surface CCR5 density determines the intensity of T cell migration towards rheumatoid arthritis synoviocytes. Clin Immunol (2007) 123:148-54. doi:10.1016/j.clim.2007.01.004
150. Bradfield PF, Amft N, Vernon-Wilson E, Exley AE, Parsonage G, Rainger GE, et al. Rheumatoid fibroblast-like synoviocytes overexpress the chemokine stromal cell-derived factor 1 (CXCL12), which supports distinct patterns and rates of CD4+ and CD8+ T cell migration within synovial tissue. Arthritis Rheum (2003) 48:2472-82. doi:10.1002/art.11219
151. Matthys P, Hatse S, Vermeire K, Wuyts A, Bridger G, Henson GW, et al. AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-gamma receptor-deficient mice. J Immunol (2001) 167:4686-92. doi:10.4049/jimmunol.167.8.4686
152. Burman A, Haworth O, Hardie DL, Amft EN, Siewert C, Jackson DG, et al. A chemokine-dependent stromal induction mechanism for aberrant lymphocyte accumulation and compromised lymphatic return in rheumatoid arthritis. J Immunol (2005) 174:1693-700. doi:10.4049/jimmunol.174.3.1693
153. Schmutz C, Hulme A, Burman A, Salmon M, Ashton B, Buckley C, et al. Chemokine receptors in the rheumatoid synovium: upregulation of CXCR5. Arthritis Res Ther (2005) 7:R217-29. doi:10.1186/ar1475
154. Takemura S, Braun A, Crowson C, Kurtin PJ, Cofield RH, O'Fallon WM, et al. Lymphoid neogenesis in rheumatoid synovitis. J Immunol (2001) 167:1072-80. doi:10.4049/jimmunol.167.2.1072
155. Bachelerie F, Ben-Baruch A, Burkhardt AM, Combadiere C, Farber JM, Graham GJ, et al. International union of basic and clinical pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev (2014) 66:1-79. doi:10.1124/pr.113.007724
156. Haringman JJ, Gerlag DM, Smeets TJ, Baeten D, van den Bosch F, Bresnihan B, et al. A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum (2006) 54:2387-92. doi:10.1002/art.21975
157. Bizzarri C, Beccari AR, Bertini R, Cavicchia MR, Giorgini S, Allegretti M. ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets. Pharmacol Ther (2006) 112:139-49. doi:10.1016/j.pharmthera.2006.04.002
158. Haringman JJ, Kraan MC, Smeets TJ, Zwinderman KH, Tak PP. Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis. Ann Rheum Dis (2003) 62:715-21. doi:10.1136/ard.62.8.715
159. Brown MF, Bahnck KB, Blumberg LC, Brissette WH, Burrell SA, Driscoll JP, et al. Piperazinyl CCR1 antagonists-optimization of human liver microsome stability. Bioorg Med Chem Lett (2007) 17:3109-12. doi:10.1016/j.bmcl.2007.03.037
160. Martinez Munoz L, Lucas P, Navarro G, Checa AI, Franco R, Martinez AC, et al. Dynamic regulation of CXCR1 and CXCR2 homo-and heterodimers. J Immunol (2009) 183:7337-46. doi:10.4049/jimmunol.0901802
161. Thelen M, Munoz LM, Rodriguez-Frade JM, Mellado M. Chemokine receptor oligomerization: functional considerations. Curr Opin Pharmacol (2010) 10:38-43. doi:10.1016/j.coph.2009.09.004
162. Barroso R, Martinez Munoz L, Barrondo S, Vega B, Holgado BL, Lucas P, et al. EBI2 regulates CXCL13-mediated responses by heterodimerization with CXCR5. FASEB J (2012) 26:4841-54. doi:10.1096/fj.12-208876
163. Pello OM, Martinez-Munoz L, Parrillas V, Serrano A, Rodriguez-Frade JM, Toro MJ, et al. Ligand stabilization of CXCR4/delta-opioid receptor heterodimers reveals a mechanism for immune response regulation. Eur J Immunol (2008) 38:537-49. doi:10.1002/eji.200737630
164. Martinez-Munoz L, Barroso R, Dyrhaug SY, Navarro G, Lucas P, Soriano SF, et al. CCR5/CD4/CXCR4 oligomerization prevents HIV-1 gp120IIIB binding to the cell surface. Proc Natl Acad Sci U S A (2014) 111:E1960-9. doi:10.1073/pnas.1322887111
165. Rodriguez-Frade JM, Vila-Coro AJ, de Ana AM, Albar JP, Martinez AC, Mellado M. The chemokine monocyte chemoattractant protein-1 induces functional responses through dimerization of its receptor CCR2. Proc Natl Acad Sci U S A (1999) 96:3628-33. doi:10.1073/pnas.96.7.3628
166. Mellado M, Rodriguez-Frade JM, Vila-Coro AJ, Fernandez S, Martin de Ana A, Jones DR, et al. Chemokine receptor homo-or heterodimerization activates distinct signaling pathways. EMBO J (2001) 20:2497-507. doi:10.1093/emboj/20.10.2497
167. Sierro F, Biben C, Martinez-Munoz L, Mellado M, Ransohoff RM, Li M, et al. Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7. Proc Natl Acad Sci U S A (2007) 104:14759-64. doi:10.1073/pnas.0702229104
168. Santiago B, Baleux F, Palao G, Gutierrez-Canas I, Ramirez JC, Arenzana-Seisdedos F, et al. CXCL12 is displayed by rheumatoid endothelial cells through its basic amino-terminal motif on heparan sulfate proteoglycans. Arthritis Res Ther (2006) 8:R43. doi:10.1186/ar1900